ADMA Biologics investors are reminded to contact BFA Law regarding a filed securities fraud class action lawsuit aimed at recovering investment losses. The update is legal/procedural in nature and does not cite financial results, but it adds ongoing litigation overhang for the stock.
ADMA Biologics investors are reminded to contact BFA Law regarding a filed securities fraud class action lawsuit aimed at recovering investment losses. The update is legal/procedural in nature and does not cite financial results, but it adds ongoing litigation overhang for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
